Private equity surge fuels hospital mergers, outpatient boom

By October 2026, the shape of the shift was visible in completed deals: Becker’s Healthcare Podcast highlighted Ascension’s $3.9 billion AmSurg purchase alongside Bon Secours Mercy’s $5.7 billion Surgery Partners deal, showing how large health systems were moving decisively into ambulatory surgery. Becker’s Hospital Review reinforced the breadth of that push with the headline “20 health systems investing in ASCs,” while Ascension’s deal, which closed in early June, made it the third-largest ASC operator in the U.S. and expanded its footprint to more than 300 surgery centers.

The expansion was not limited to acquisitions; it was also showing up in operating footprints and access metrics across outpatient care. Becker’s Healthcare reported that Ascension had added primary care physicians steadily and cut average patient wait times by three days while tracking “unique lives served” and “primary care access times,” and MU Health Care said 2026 had been “a busy year, but a strong year for execution,” citing growing demand for specialty and outpatient care and “Lots of progress expanding capacity… like cardiology, surgical services, neurosciences, infusion services and endoscopy.”

Private equity firms and health systems are not relying on a single transaction model; they are stitching together acquisitions, vertical integration, and operating partnerships to control more of the outpatient pathway. In Growth Opportunities and Strategic Partnerships in Healthcare, one speaker said hospitals increasingly must consider private equity in “insurance, managed care and Medicare Advantage programs,” as well as “value based care, ACOs” and acquisitions, while also stressing that partnership choices now turn on “compliance, legality” and the financial mechanics of “DRGs to CPTs,” reimbursement, and contracting methodologies.

That same logic is pushing care outside the hospital through structures that blend physicians, management companies, capital providers, and health systems into a shared outpatient platform. Why Ambulatory Surgery Centers Are Booming and How Physicians Can Profit describes ASCs as “a perfect area for collaboration and joint ventures,” while Growth Opportunities and Strategic Partnerships in Healthcare says Medicare population growth rose “almost by 20 to 25%” in four years, leading to “more and more ambulatory surgery centers… to meet the population needs,” even as systems still “need providers” and “need to collaborate on that part of it.”

The financial squeeze showed up first in the pricing signals running through the insurance market. A July 8 Peterson-KFF Health System Tracker analysis, updated Aug. 3, said ACA insurers were seeking “a median rate increase of 15% for 2027,” while citing “steeper healthcare costs” and a median medical trend of “10% for 2027” — a sign that the cost base confronting hospitals and health systems was still rising fast enough to make standalone operations harder to sustain without added scale or outside capital.

At the same time, the revenue side was getting less predictable, tightening payer economics and making strategic combinations more attractive. Insurers said higher rates were also driven by “the expiration of enhanced premium tax credits” and “greater morbidity in risk pools,” with premium payments rising “58% on average in 2026” after the credits expired; they also pointed to “No Surprises Act disputes” and said “regulatory changes and HR 1 played a role,” underscoring how payer mix pressure and policy uncertainty were pushing systems toward mergers and asset sales.

The sharpest objections come from patient-safety and accountability critics, who argue that private equity’s incentives can conflict with care delivery. The Guardian reported that PESP detailed more than 500 joint ventures between private equity and non-profit healthcare providers, spanning rural hospitals, major religiously affiliated health systems, and hospice care providers; critics say that breadth warrants scrutiny because private ownership can obscure oversight, while a widely cited JAMA study found hospitals acquired by PE firms saw a 25.4 percent increase in hospital-acquired adverse events relative to matched controls, especially falls and central line infections.

Critics also argue the financial engineering behind some deals can weaken care quality and amplify market power rather than stabilize medicine. The Guardian cited NYU researchers saying private equity invested more than $1tn in debt-financed healthcare deals in the last decade, while lawmakers and academics argue debt-fueled buying and short investment horizons are at odds with medicine; after Steward Health’s bankruptcy, it had $9bn in debt by 2024 and hundreds of millions in profit extracted for investors, yet defenders still contend such transactions can preserve access and hospital finances under IRS joint-venture rules dating to 1998 and 2004.